WO2008022541A1 - Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation - Google Patents

Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation Download PDF

Info

Publication number
WO2008022541A1
WO2008022541A1 PCT/CN2007/002411 CN2007002411W WO2008022541A1 WO 2008022541 A1 WO2008022541 A1 WO 2008022541A1 CN 2007002411 W CN2007002411 W CN 2007002411W WO 2008022541 A1 WO2008022541 A1 WO 2008022541A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
organic solvent
solvent
derivative
diisopropylphenol
Prior art date
Application number
PCT/CN2007/002411
Other languages
English (en)
French (fr)
Inventor
Qinggeng Li
Daihua Li
Rui Tian
Jingyuan Wang
Tao Wang
Pan Chen
Yangqiang Sun
Liang He
Original Assignee
Qinggeng Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qinggeng Li filed Critical Qinggeng Li
Publication of WO2008022541A1 publication Critical patent/WO2008022541A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Definitions

  • the present invention relates to a series of water-soluble derivatives containing 2,6-diisopropylphenol and a process for the preparation thereof. Background technique
  • 2,6-Diisopropylphenol (propofol, propofol), a short-acting intravenous general anesthetic with rapid onset, no obvious accumulation, quick and complete recovery, and its injection is clinically used for general anesthesia. Induction and maintenance. However, due to its low solubility in water, it can only be applied to the clinic in the form of an emulsion. However, the emulsion has a poor physical stability; 2. The larger oil droplet size may cause embolism; 3. The injection causes pain; 4. It can only be selectively mixed with a small number of injectable products before administration; 5. The emulsion is easy to fine ⁇ Growth; 6, causing side effects such as toxic side effects, limiting the use of 2,6-diisopropylphenol. Summary of the invention
  • the object of the present invention is to provide a water-soluble 2, 6 by using a hydroxyl group in 2,6-diisopropylphenol to form a series of tertiary amine-containing derivatives by chemical reaction, and then using a tertiary amine to form a salt with an acid.
  • a method of a series of prodrugs of diisopropylphenol Such prodrugs can quickly hydrolyze 2,6-diisopropylphenol by injection into the body, producing an anesthetic effect, overcoming the disadvantage of poor water solubility of 2,6-diisopropylphenol.
  • the invention relates to a general formula of
  • the structural formula of the nitrogen atom-containing organic group is as follows:
  • R 3 , R 4 H, R 1 , F, CI, Br , N0 2 , OR 1 ; R 3 , R 4 relative positions may be adjacent, inter-, para)
  • the corresponding acid HB means hydrochloric acid, phosphoric acid, sulfuric acid, carbonic acid, etc.
  • the inorganic acid used; or acetic acid, lactic acid, methanesulfonic acid, succinic acid, citric acid, malic acid or the like can be used as a medicinal organic acid.
  • the present invention obtains the above derivative (11) by using four methods from 2,6-diisopropylphenol (I).
  • the synthesis method specifically includes:
  • the ester is formed by reacting 2,6-diisopropylphenol (I) with an optionally substituted halohalide halide in an organic solvent, and a pyridine or a tertiary amine may be added as a catalyst or an acid remover in the reaction.
  • the reaction temperature is -50 ° C; then form a salt with the corresponding acid in a solvent, here, if water is used
  • the solvent can be obtained by freeze-drying (II); if an organic solvent is used, the obtained crystals can be dried by filtration, under reduced pressure or under normal pressure (11).
  • Process B (I) reacting with a halogenated acid which can be substituted in an organic solvent under the action of DCC, or DCC/DMAP, or other corresponding active substance to form a halogenated ester, and then using a secondary amine in an organic solvent
  • the compound is substituted with a halogen to form a nitrogen-containing compound, and the reaction temperature is -20 ⁇ - 50 ° C; and then a salt is formed in a solvent with a corresponding acid, and if it is used as a solvent, it can be obtained by freeze-drying (II); if an organic solvent is used, The obtained crystals can be dried by filtration, under reduced pressure or under normal pressure (11).
  • Method C (I) reacting with a tertiary amine-containing carboxylic acid in an organic solvent under the action of DCC, or DCC/DMAP, or other corresponding active substance to form a tertiary amine-containing ester, the reaction temperature is -20 ° C - 50 Torr; Then forming a salt with the corresponding acid in a solvent, where if it is used as a solvent, it can be freeze-dried. (II); if an organic solvent is used, the obtained crystals can be dried by filtration, under reduced pressure or under normal pressure to give (11).
  • Process D (I) reacting with a tertiary amine-containing acid halide hydrochloride in an organic solvent, or reacting with a pyridine or DMAP or a tertiary amine or other corresponding active substance to form a tertiary amine-containing ester, the reaction Temperature -20 ⁇ - 5 CTC; then salt with the corresponding acid in the solvent, here, if water is used as a solvent, it can be dried by freezing (II); if using an organic solvent, the resulting crystal can be filtered, decompressed or Dry under normal pressure ( ⁇ ).
  • the 2,6-diisopropylphenyl derivative (II) of the present invention can be used for the production of anesthetic effects in animals and humans.
  • the invention forms a tertiary amine derivative by chemical reaction without changing the inherent pharmacological activity of 2,6-diisopropylphenol, and then forms a prodrug with a salt to improve the water solubility and reduce the side effects. , increase its scope of application. detailed description

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

麻醉药 2,6-二异丙基苯酚的水溶性衍生物及其制备方法
技术领域
本发明涉及一系列含 2, 6-二异丙基苯酚的水溶性衍生物及其制备方法。 背景技术
2, 6-二异丙基苯酚(丙泊酚, 异丙酚), 为短效静脉全身麻醉药, 起效 迅速, 无明显蓄积, 苏醒快而完全, 其注射液临床上用于全身麻醉的诱导和 维持。 但是因其水中溶解度很小而只能以乳剂的形式应用于临床。 然而乳剂 具有 1、 物理稳定性差; 2、 由于较大的油滴尺寸可能导致栓塞; 3、 注射引 起疼痛; 4、 在用药前仅能与少数可注射产品选择性混合; 5、 乳剂易于细 ^ 生长; 6、引起心脏方面毒副作用等缺点, 限制了 2, 6-二异丙基苯酚的使用。 发明内容
本发明的目的是提供利用 2, 6-二异丙基苯酚中的羟基, 通过化学反应 使其成为一系列含叔胺的衍生物, 再利用叔胺与酸成盐, 制备出水溶性 2, 6-二异丙基苯酚一系列前药的方法。 这类前药通过注射进入体内后可很快水 解释放出 2, 6-二异丙基苯酚, 产生麻醉效应, 克服 2, 6-二异丙基苯酚水溶 性差的缺点。
本发明涉及一种通式为
Figure imgf000003_0001
的系列化合物, 其中 n=0-7, R=H, 甲基, 乙基, D代表含有氮原子的有机 基团及与相应酸成的盐。 所述的含氮原子的有机基团的结构式如下:
1
确认本 I'R1 (R1,R2=,CH3,CH2CH2CH3, CH2CH2CH2CH3 Ar,CH2Ar;
Figure imgf000004_0001
、:R H c2 '
2
R3,R4=H, R1, F, CI, Br , N02, OR1 ; R3,R4 的相对位置可是邻,间,对位 )
-N— (CH2)n (n=1 , 2, 5, 6) (R5,R6=H,CH3,CH2CH3,CH2CH2CH3; A=S;当 R5,R6不同时为 H时 A=CH2, 0, NR7;
Figure imgf000004_0002
R7=H, CH3, CH2CH3,CH2CH2CH3,i-Pr,Ph,CH2Ph) 在这里, 相应的酸 HB是指盐酸, 磷酸, 硫酸, 碳酸等可作为药用的无 机酸; 或乙酸, 乳酸, 甲磺酸, 丁二酸, 枸櫞酸, 苹果酸等可作为药用的有 机酸。
本发明以 2, 6-二异丙基苯酚 (I) 为原料使用四种方法获得上述衍生物 (11)。
Figure imgf000004_0003
其合成方法具体包括:
方法 A: 通过 2,6-二异丙基苯酚(I)在有机溶剂中与可被取代的卤代酰 卤反应形成酯, 反应中也可加入吡啶或叔胺作催化剂或去酸剂, 反应温度 -78 °C_回流; 再在有机溶剂中用含仲胺的化合物取代卤素形成含氮物, 反应温 度 — 50°C ; 然后在溶剂中与相应的酸成盐, 在这里, 如果用水作溶剂, 可通过冷冻干燥得(II); 如果用有机溶剂, 所得的结晶可通过过滤, 减压或 常压下干燥得 (11)。
Figure imgf000005_0001
方法 B: (I)在有机溶剂中与可被取代的卤代酸在 DCC,或 DCC/DMAP, 或其他相应的活性物质作用下反应形成卤代酯, 再在有机溶剂中用含仲胺的 化合物取代卤素形成含氮物, 反应温度 -20Ό— 50°C; 然后在溶剂中与相应的 酸成盐, 在这里, 如果用水作溶剂, 可通过冷冻干燥得 (II); 如果用有机溶 剂, 所得的结晶可通过过滤, 减压或常压下干燥得 (11)。
Figure imgf000005_0002
方法 C: (I)在有机溶剂中与含叔胺的羧酸在 DCC, 或 DCC/DMAP, 或其他相应的活性物质作用下反应形成含叔胺的酯, 反应温度 -20°C— 50Ό; 然后在溶剂中与相应的酸成盐, 在这里, 如果用水作溶剂, 可通过冷冻干燥 得(II);如果用有机溶剂,所得的结晶可通过过滤,减压或常压下干燥得(11)。
Figure imgf000006_0001
方法 D: (I) 在有机溶剂中与含叔胺的酰卤盐酸盐反应,, 亦可在吡啶 或 DMAP或叔胺,或其他相应的活性物质作用下反应形成含叔胺的酯,反应 温度 -20Ό— 5CTC ;然后在溶剂中与相应的酸成盐,在这里,如果用水作溶剂, 可通过冷冻千燥得(II); 如果用有机溶剂, 所得的结晶可通过过滤, 减压或 常压下干燥得 (Π)。
Figure imgf000006_0002
本发明所述的含 2, 6-二异丙基苯基的衍生物 (II) 可用于产生动物及 人的麻醉作用。
本发明在不改变 2, 6-二异丙基苯酚固有的药理活性的前提下, 通过化 学反应形成叔胺衍生物, 然后与酸成盐制成前药, 从而改善其水溶性, 减少 毒副作用, 增加其适用范围。 具体实施方式
实施例 1
用氯乙酰氯制备 2, 6-二异丙基苯基 -2-氯乙酸酯: 在干燥 N2流下,于 100ml干燥的三口瓶中加入 30ml无水乙醚, 5.13g 2, 6-二异丙基苯酚, 以及氯乙酰氯 3.0ml。 冷却降温至一 5 °C左右; 缓缓加入 5g吡啶。 控制内温在一 5 °C± 2 °C。 滴加完毕后, 移去冰盐浴, 于室温下自 然升温, 并在室温下继续反应 4小时, 直至反应完全为止。 抽滤, 滤液用冰 盐水洗涤, 直至水层为中性, 然后用无水 Na2 S 0 4干燥; 抽滤, 滤液减压 浓缩, 蒸尽乙醚, 得油状物 7.2g, 收率 95%。
实施例 2
用氯乙酸制备 2, 6-二异丙基苯基 -2-氯乙酸酯: 在干燥 N2流下,于 100ml干燥的三口瓶中加入 30ml二氯甲烷, 5.13g2, 6-二异丙基苯酚, 以及氯乙酸 2.8g。 适量 DCC。 于室温反应 3小时以上, 加 入 10ml稀盐酸搅拌 1小时以上, 分去水层, 减压挥去溶剂, 得油状物 6.5g, 收率 88%。 实施例 3
用 2, 6-二异丙基苯基 -2-氯乙酸酯制备 N, N- 2, 6-二异丙基苯基 -2-二甲氨基 乙酸酯盐酸盐
将 2, 6-二异丙基苯基 -2-氯乙酸酯 7.2g溶于 50ml丙酮, 搅拌下, 通入 干燥的二甲胺气体, 反应至终点; 减压浓缩, 加乙醚 2 ϋ ml溶解油状液体, 用 1 Q ml饱和碳酸氢钠溶液洗搽,然后再用饱和冰盐水洗涤,直至水层为中 性; 有机层用无水 Na2 S 0 4干燥, 抽滤, 搅拌下, 缓慢通入干燥的氯化氢 气体, 抽滤, 得白色的固体 6.8g, 收率 80%; 取粗品 0.66g, 加入 45ml丙酮, 少量活性炭搅拌加热回流脱色, 过滤, 加入适量乙醚, 冷冻结晶, 抽滤, 用 少量乙醚洗涤,于 50°C烘箱内减压干燥,得白色结晶性固体 0.47g,收率 71%, 熔点大于 200 °C。
实施例 4
用 N, N-二甲基甘氨酰氯盐酸盐制备 N, N-2, 6-二异丙基苯基 -2-二甲氨基 乙酸酯盐酸盐
在干燥 N2流下,于 100ml干燥的三口瓶中加入 30ml无水二氯甲烷,5.13g 2, 6-二异丙基苯酚, 以及 8.6g N, N-二甲基甘氨酰氯盐酸盐, 冷却降温至一 5。C左右,缓缓加入 5g吡啶。 反应 1小时以上, 加入 10ml稀氢氧化钠, 分 去有水层,有机层用水洗涤至中性后用无水硫酸钠干燥,减压挥去有机溶剂, 得白色固体; 取粗品 Q .8g, 加入 50ml丙酮, 少量活性炭搅拌加热回流脱色, 过滤, 加入适量乙醚, 冷冻结晶, 抽滤, 用少量乙醚洗涤, 于 50°C烘箱内减 压干燥, 得白色结晶性固体 0 .56g, 收率 70%, 熔点大于 200 °C。
实施例 5 ·
用 N, N-二甲基甘胺酸制备 N, N-2, 6-二异丙基苯基 -2-二甲氨基乙酸酯盐 酸盐
在干燥 N2流下,于 100ml干燥的三口瓶中加入 30ml无水二氯甲烷,5.13g 2, 6-二异丙基苯酚, 以及 3g N, N-二甲基甘氨酸, 适量 DCC:。 于室温反应 3小时以上, 加入 10ml稀盐酸搅拌 1小时以上, 分去有机层, 水层过滤, 加 氢氧化钠溶液至 pH约 8,用二氯甲烷提取水层 3次;有机层用水洗涤至中性 后用无水硫酸钠干燥,减压挥去有机溶剂,得白色固体;取粗品 lg,加入 55ml 丙酮, 少量活性炭搅拌加热回流脱色, 过滤, 加入适量乙醚, 冷冻结晶, 抽 滤, 用少量乙醚洗涤, 于 50。C烘箱内减压干 '燥, 得白色结晶性固体 Q .7g, 收率 70%, 熔点大于 200。C。

Claims

权 利 要 求 书
1、一系列含 2, 6-二异丙基苯基的衍生物, 其特征在于该衍生物具有下列通 式:
Figure imgf000010_0001
其中 n=0-7, R=H, 甲基, 乙基, D代表含有氮原子的有机基团, HB是 指与有机基团成盐的并可作为药用的无机酸或有机酸, 所述含氮原子的有机 基团的结构式如下: 位 )
Figure imgf000010_0002
— N A (R5,R6=H,CH3,CH2CH3,CH2CH2CH3; A=S;当 R5,R6不同吋为 [-)时 A=CH2, O, NR
R6 R7=H, CH3, CH2CH3,CH2CH2CH3,i-Pr,Ph,CH2Ph)
2、 根据权利要求 1所述含 2, 6-二异丙基苯基的衍生物, 其特征在于: HB 是指可作为药用的无机酸盐酸、 磷酸、 硫酸或碳酸; 或可作为药用的有机酸 乙酸、 乳酸、 甲磺酸、 丁二酸、 枸橼酸或苹果酸。
3、 权利要求 1所述衍生物的合成方法, 其特征在于该方法是:
通过 2,6-二异丙基苯酚(I)在有机溶剂中与可被取代的卤代酰氯反应形 成酯, 反应中也可加入吡啶或叔胺作催化剂或去酸剂, 反应温度- 78°C—回流 温度; 再在有机溶剂中用含仲胺的化合物取代卤素形成含氮物, 反应温度 -20 °C-50°C ; 然后在溶剂中与相应的酸 HB成盐, 最后得到衍生物 (11)。
4、 权利要求 1所述化合物的合成方法, 其特征在于该方法是: 通过 2,6-二异丙基苯酚 (I) 在有机溶剂中与可被取代的卤代酸在 DCC, 或 DCC/DMAP,或其他相应的活性物质作用下反应形成卤代酯;再在有机溶 剂中用含仲胺的化合物取代卤素形成含氮物, 反应温度- 20°C— 50°C ; 然后在 溶剂中与相应的酸成盐, 最后得到衍生物 (11)。
5、 权利要求 1所述化合物的合成方法, 其特征在于该方法是:
通过 2,6-二异丙基苯酚 (I) 在有机溶剂中与含叔胺的羧酸在 DCC或 DCC/DMAP, 或其他相应的活性物质作用下反应形成含叔胺的酯, 反应温度 -20Ό— 50°C ; 然后在溶剂中与相应的酸成盐, 最后得到衍生物 (11)。
6、 权利要求 1所述化合物的合成方法, 其特征在于该方法是:
通过 2,6-二异丙基苯酚(I)在有机溶剂中与含叔胺的酰卤盐酸盐反应, 亦可在吡啶或 DMAP或叔胺,或其他相应的活性物质作用下反应形成含叔胺 的酯, 反应温度 -2CTC— 50Ό ; 然后在溶剂中与相应的酸成盐, 最后得到衍生 物 (11)。
7、根据权利要求 3-6之任意一项所述的方法, 其特征在于: 所说的有机溶剂 为含卤素的有机溶剂二氯甲垸、 氯仿或氯苯; 或不含卤素的有机溶剂苯、 甲 苯、 己烷或环己垸; 或含其他杂原子的有机溶剂乙腈、丙酮、 DMF、 DMSO、 THF或乙醚。 .
8、根据权利要求 3-6之任意一项所述的方法, 其特征在于: 所述在溶剂中与 相应的酸 HB成盐步骤中的溶剂指的是水或有机溶剂; 用水作溶剂时, 通过 冷冻干燥得衍生物 (II) ; 用有机溶剂时, 所得的结晶通过过滤, 千燥得衍生 物 (11), 千燥在减压或常压下进行。
9、根据权利要求 3所述的方法,其特征在于,所说的卤代酰氯中的卤原子为 氯或溴。
10、 将权利要求 1所述的含 2, 6-二异丙基苯基的衍生物(Π)用于制备对动 物及人产生麻醉作用的麻醉药。
PCT/CN2007/002411 2006-08-16 2007-08-13 Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation WO2008022541A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610095042.3 2006-08-16
CN2006100950423A CN1907954B (zh) 2006-08-16 2006-08-16 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法

Publications (1)

Publication Number Publication Date
WO2008022541A1 true WO2008022541A1 (fr) 2008-02-28

Family

ID=37699207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/002411 WO2008022541A1 (fr) 2006-08-16 2007-08-13 Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation

Country Status (2)

Country Link
CN (1) CN1907954B (zh)
WO (1) WO2008022541A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113788761A (zh) * 2021-08-13 2021-12-14 丽江映华生物药业有限公司 一种医药中间体的精制方法和系统

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
CN101716149B (zh) * 2009-11-30 2013-04-10 宜昌人福药业有限责任公司 一种新的前体药物制剂
CN102190622B (zh) * 2010-03-15 2015-01-07 李勤耕 依达拉奉的水溶性衍生物及其制备方法和应用
CN102516099B (zh) * 2011-12-02 2013-07-17 成都苑东药业有限公司 一种水溶性三醇胺的衍生物
CN106029631B (zh) * 2014-02-17 2018-12-28 李勤耕 一类羧酸衍生物及其在制备前药中的用途
US9643917B2 (en) 2014-02-17 2017-05-09 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Water-soluble propofol derivatives and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046575A2 (en) * 2003-07-29 2005-05-26 Signature R & D Holdings, Lcc Amino acid prodrugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046575A2 (en) * 2003-07-29 2005-05-26 Signature R & D Holdings, Lcc Amino acid prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRAPANI G. ET AL.: "Water-soluble salts of amino acid esters of the anesthetic agent propofol", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 175, no. 2, 1998, pages 195 - 204, XP002112863, DOI: doi:10.1016/S0378-5173(98)00284-1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113788761A (zh) * 2021-08-13 2021-12-14 丽江映华生物药业有限公司 一种医药中间体的精制方法和系统

Also Published As

Publication number Publication date
CN1907954A (zh) 2007-02-07
CN1907954B (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
WO2008022541A1 (fr) Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation
RU2679891C2 (ru) Новые аминоалкилбензотиазепиновые производные и их применение
KR101614465B1 (ko) 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
CA2790924C (en) Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
JP5856156B2 (ja) 置換フェノールを含むヒドロキシ酸エステル化合物、その製造方法及びそれを用いた中枢抑制薬
JP5650320B2 (ja) 置換フェノールを含むヒドロキシ酸エステルのリン酸エステル化合物、その製造方法及びそれを用いた中枢抑制薬
KR20070083471A (ko) 시나칼셋 염산염 결정형 i의 제조 방법
RU2417217C2 (ru) Устойчивые и стабильные при хранении солевые кластеры соли аммония и минеральной соли с анионами двухосновных кислот и способ их получения
IL194329A (en) Crystalline form of tigecycline ii and its processes
JP2009173621A (ja) 2−アミノ−n−(2,2,2−トリフルオロエチル)アセトアミド化合物又はその塩の製造方法
WO2015120821A1 (zh) 一类水溶性丙泊酚衍生物及其用途
CN102382005A (zh) 含氨基羧酸酰胺结构的丙泊酚酯类衍生物、制备方法及其用途
JP2011511053A (ja) ボリノスタットの新規な製造方法
JP6670744B2 (ja) ヒオデオキシコール酸ナトリウム(NaHDC)の多形形態およびその調製方法
KR101247137B1 (ko) N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
KR100877134B1 (ko) 아캄프로세이트 칼슘의 제조방법
AT405402B (de) Kristalline salze von 7-(2-(aminothiazol-4-yl)-2 -(tert.butoxycarbonylmethoxyimino)acetamido)- 3-vinyl-3-cephem-4-carbonsäure
EP3351530B1 (en) Method of producing a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulphanilic acid
CN102020574B (zh) 丙泊酚γ-氨基丁酸酯的衍生物及其制备方法
KR101366706B1 (ko) N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
CN118206481A (zh) 一类2-羟基烟酸的右崁醇或葑醇酯类衍生物及其药物用途
CN117209499A (zh) 厄他培南酰胺物的制备方法及其在制剂质量研究中的应用
KR100751888B1 (ko) 5-(치환된 페닐 알킬)아미노살리실산 화합물의 약학적으로허용 가능한 염의 제조방법
CN109180511A (zh) 一种盐酸丁卡因的制备方法
CA2154423A1 (en) Phosphorylated derivatives of compositions having anti-inflammatory or analgesic activity and a method for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800692

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07800692

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)